(RTTNews) - Shares of Corvus Pharmaceuticals, Inc. (CRVS) jumped nearly 30% on Monday morning after the drug maker reported positive results from an early stage study of investigational COVID-19 treatment. CRVS is currently trading at $5.20, up $1.13 or 27.76%, on the Nasdaq. The clinical-stage biopharmaceutical company said that new data from phase 1 study of CPI-006, which is intended to improve immune system by producing anti-SARS-CoV-2 antibodies, continues to support its potential as a treatment for COVID-19.